Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serabelisib + Insulin Suppressing Diet +/- Nab-paclitaxel in Advanced Solid Tumors
NCT05300048Phase 1Terminated
- Sponsor
- Faeth Therapeutics
- Start
- Apr 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of serabelisib in solid tumor, endometrial cancer (EC), ovarian clear cell carcinoma (OCCC) and 2 more (5 cohorts), sponsored by Faeth Therapeutics. Primary endpoints: Safety and Tolerability up to 12 months, Treatment Compliance up to 12 months and 4 more. Started Apr 2022; status: terminated.
02
Drugs
serabelisib
03
Conditions
solid tumorendometrial cancer (EC)ovarian clear cell carcinoma (OCCC)ovarian endometrioid carcinoma (OEC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05300048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05300048.